Alnylam Pharmaceuticals said this week that Vicki Sato has been elected to the company's board of directors.
Sato was formerly president of Vertex Pharmaceuticals. Before this, she served as the company's CSO and chief of the scientific advisory board. Prior to joining Vertex, she held various positions at Biogen.
She holds a BS, MS, and PhD from Harvard University.
Lentigen said last week that it has named three new members of its management team (see full story, this issue).
Joining the company is Yung Nien Chang, formerly vice president of research and development at VirxSys, as vice president of vector development.
Before working at VirxSys, Chang was a senior scientist and group leader at Genetic Therapy, which later merged with Novartis. He holds a PhD in biology from the University of North Texas, an MS from the National Defense Medial Center in Taiwan, and a BS from Tunghai University.
Lentigen also said that it has tapped Gregory Feulner to be the company's vice president of business development. Prior to joining Lentigen, Feulner held similar positions at Galileo Genomics and Gene Logic. He holds a BS in biology and chemistry from the University of Delaware, a PhD in biochemistry from Pennsylvania State University, and a JD from Syracuse College of Law.
Lentigen also said that John Woolford has been named the company's director of business planning. Most recently, he was a vice president and equity analyst at Legg Mason Wood Walker, where he followed the biotechnology and life science sectors. He has also held positions in the contract manufacturing division of MedImmune. He holds an MBA and a BS in microbiology from the University of Maryland.